Backing the Science That Changes Medicine

James Landing Capital is an early-stage investment firm focused exclusively on Biopharma and Medtech. We typically back founders at the seed and Series A stages — when the science is compelling, but the path is still being defined.

We take a concentrated approach, working closely with a small number of portfolio companies at a time. Our value is not just capital — it is judgment, network, and the willingness to engage deeply with the scientific and commercial challenges that define this space.

We are long-term partners. We value successful technical and clinical outcomes as much as IRR.

Alex Euler has spent nearly two decades at the intersection of life sciences and venture capital. In addition to founding James Landing Capital, he holds investment roles at Virginia Venture Partners, where he leads a team of investment professionals who make early-stage venture capital investments across sectors, with a primary focus on biopharma, medtech, and healthcare. Over the last 15 years, Alex has led over 300 transactions, including first-time investments, follow-on financings, exits via M&A, VC secondaries, joint ventures, and option agreements.

Alex holds degrees in molecular biology and business and brings an analytical rigor to every investment decision. He is particularly drawn to platform technologies with the potential to address large, underserved disease areas.